Candida auris Isolates Resistant to Three Classes of Antifungal Medications — New York, 2019
10 January 2020
Three years after the first identification of C. aurisin New York, pan-resistant isolates remain rare. Continued surveillance for C. auris, prudent antifungal use, and susceptibility testing for all C. aurisclinical isolates (especially after patients have been treated with antifungal drugs) are needed.
Further reading: CDC
Author(s): Belinda Ostrowsky, Jane Greenko, Eleanor Adams, Monica Quinn, Brittany O’Brien, Vishnu Chaturvedi, Elizabeth Berkow, Snigdha Vallabhaneni, Kaitlin Forsberg, Sudha Chaturvedi, Emily Lutterloh, Debra Blog
Effective Surveillance
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
 |
BD |
AMR NEWS
Your Biweekly Source for Global AMR Insights!
Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.
Don’t miss out on staying ahead in the global AMR movement—subscribe now!